What does Craig Good think of multivitamins

Plus epicatechin Duchenne muscular dystrophy in non-ambulatory adolescents

Inclusion criteria:

- Male

- Age 8 to 17 years

- Not outpatient (10 m running / walking for less than 10 s not possible)

- Weight

- Diagnosis of DMD confirmed by at least one of the following:

- Dystrophin immunofluorescence and / or immunoblot with complete dystrophin deficiency and clinical picture consistent with typical DMD or

- Gene deletions test positive (without one or more exons) of the dystrophin gene. The reading frame can be predicted as "out of frame" and as a clinical picture consistent with typical DMD or

- Complete dystrophin gene sequencing with changes (point mutation, duplication or other mutation that leads to a stop codon mutation) that can be definitely associated with DMD, with a typical clinical picture of DMD, or

- Positive family history of DMD, confirmed by one of the criteria listed in a above, siblings or uncle on the mother's side and a clinical picture typical of DMD.

- Cardiac ejection fraction> 55% on the echocardiogram

- Use of dietary supplements, herbs, and antioxidants with the intent to maintain or improve skeletal muscle strength or functional mobility was discontinued at least 4 weeks prior to screening (daily multivitamin use is acceptable).

- Glucocorticoid therapy, if used, must have a stable weight-based dose of at least 3 months prior to enrollment

Cardiac therapy, if used, includes prophylactic ACE inhibitors, aldosterone receptor antagonists (e.g.

Spironolactone, eplerenone etc.) and / or beta blocker therapy and must be stable for 3 months prior to enrollment.

- Hematology profile in the normal range.

- Basic profile of laboratory safety chemistry in the typical range for DMD (elevated) ALT / AST acceptable in the absence of elevated GGT, elevated CK acceptable).

Exclusion criteria:

- Inability to perform heart or strength, range of motion, and mobility assessments per protocol

- Currently enrolled in another clinical treatment study.

- History of significant comorbidities or significant impairment of kidney or kidney disease, liver function.

- Use of regular daily aspirin or other antiplatelet drugs within 3 weeks of the first dose of study medication.

- Cardiac symptoms that the investigator believes may indicate impending moderate to severe cardiac events, regardless of LVEF.